NasdaqGS:CAPRBiotechs
A Look At Capricor Therapeutics’ (CAPR) Valuation After FDA Resumes Deramiocel Review On New HOPE-3 Data
Capricor Therapeutics (CAPR) is back in focus after the FDA resumed review of its Biologics License Application for Deramiocel, supported by new HOPE-3 Phase 3 data in Duchenne muscular dystrophy cardiomyopathy.
See our latest analysis for Capricor Therapeutics.
The FDA decision and fresh HOPE-3 data arrived after a strong run, with a 30 day share price return of 35.86% and a one year total shareholder return of 130.54%. This comes even though the stock has pulled back 8.74% on the day to...